Pharmaceutical Industry Special Equity Act of 1996

Summary

Prescription Drug Equity Act of 1995 - Declares that it is the sense of the Senate that the generic drug industry should be provided equitable relief in the manner other industries are provided such relief under certain Federal law patent transitional provisions, as amended by the Uruguay Round Agreements Act of 1994. Regulates the patent expiration date regarding new drug and new animal drug applications submitted before June 8, 1995 (or submitted after that date but with substantial investment before that date). Declares that the remedies of certain patent provisions shall not apply to acts that were commenced (or that had substantial investment) before that date and that became infringing by reason of specified provisions of the Uruguay Round Agreements Act. Restricts the circumstances in which equitable remuneration may be awarded. Specifies the application approval circumstances to which this Act applies.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

6 official files

• Reported to Senate (text)

  Reported to Senate · EN · 1 October 1996

  ViewDownloadOpen at official source

• Reported to Senate (PDF)

  Reported to Senate · EN · 1 October 1996

  ViewDownloadOpen at official source

• Reported to Senate with amendment(s)

  summary · EN · 1 October 1996

  Open at official source

• Introduced in Senate (text)

  Introduced in Senate · EN · 27 September 1995

  ViewDownloadOpen at official source

• Introduced in Senate (PDF)

  Introduced in Senate · EN · 27 September 1995

  ViewDownloadOpen at official source

• Introduced in Senate

  summary · EN · 27 September 1995

  Open at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.